Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Zentalis Pharmaceuticals stock | $77.23

Learn how to easily invest in Zentalis Pharmaceuticals stock.

Zentalis Pharmaceuticals Inc is a biotechnology business based in the US. Zentalis Pharmaceuticals shares (ZNTL) are listed on the NASDAQ and all prices are listed in US Dollars. Zentalis Pharmaceuticals employs 124 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Zentalis Pharmaceuticals

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ZNTL – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Zentalis Pharmaceuticals stock price (NASDAQ: ZNTL)

Use our graph to track the performance of ZNTL stocks over time.

Zentalis Pharmaceuticals shares at a glance

Information last updated 2021-10-16.
Latest market close$77.23
52-week range$34.48 - $81.40
50-day moving average $69.08
200-day moving average $56.83
Wall St. target price$81.78
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-4.50

Buy Zentalis Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Robinhood
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
N/A
$20 per year
N/A
Financial advice powered by relationships, not commissions.
TradeStation
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Moomoo
Stocks
$0
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Zentalis Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Zentalis Pharmaceuticals price performance over time

Historical closes compared with the close of $77.23 from 2021-10-20

1 week (2021-10-14) -0.89%
1 month (2021-09-21) 16.79%
3 months (2021-07-21) 52.66%
6 months (2021-04-21) 41.50%
1 year (2020-10-21) 90.41%
2 years (2019-10-17) N/A
3 years (2018-10-17) N/A
5 years (2016-10-17) N/A

Zentalis Pharmaceuticals financials

Gross profit TTM $0
Return on assets TTM -41.69%
Return on equity TTM -74.36%
Profit margin 0%
Book value $5.42
Market capitalisation $3.4 billion

TTM: trailing 12 months

Shorting Zentalis Pharmaceuticals shares

There are currently 2.5 million Zentalis Pharmaceuticals shares held short by investors – that's known as Zentalis Pharmaceuticals's "short interest". This figure is 8% up from 2.3 million last month.

There are a few different ways that this level of interest in shorting Zentalis Pharmaceuticals shares can be evaluated.

Zentalis Pharmaceuticals's "short interest ratio" (SIR)

Zentalis Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Zentalis Pharmaceuticals shares currently shorted divided by the average quantity of Zentalis Pharmaceuticals shares traded daily (recently around 303621.68087698). Zentalis Pharmaceuticals's SIR currently stands at 8.21. In other words for every 100,000 Zentalis Pharmaceuticals shares traded daily on the market, roughly 8210 shares are currently held short.

However Zentalis Pharmaceuticals's short interest can also be evaluated against the total number of Zentalis Pharmaceuticals shares, or, against the total number of tradable Zentalis Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Zentalis Pharmaceuticals's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Zentalis Pharmaceuticals shares in existence, roughly 60 shares are currently held short) or 0.0795% of the tradable shares (for every 100,000 tradable Zentalis Pharmaceuticals shares, roughly 80 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Zentalis Pharmaceuticals.

Find out more about how you can short Zentalis Pharmaceuticals stock.

Zentalis Pharmaceuticals share dividends

We're not expecting Zentalis Pharmaceuticals to pay a dividend over the next 12 months.

Zentalis Pharmaceuticals overview

Zentalis Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidates are the ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer; and ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, as well as in Phase 1b clinical trial in combination with chemotherapy in patients with advanced ovarian cancer. The company also develops ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Zentalis Pharmaceuticals has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd. ; Pfizer, Inc. ; Eli Lilly and Company; and Zentera Therapeutics (Cayman), Ltd.

Frequently asked questions

What percentage of Zentalis Pharmaceuticals is owned by insiders or institutions?
Currently 9.294% of Zentalis Pharmaceuticals shares are held by insiders and 91.028% by institutions.
How many people work for Zentalis Pharmaceuticals?
Latest data suggests 124 work at Zentalis Pharmaceuticals.
When does the fiscal year end for Zentalis Pharmaceuticals?
Zentalis Pharmaceuticals's fiscal year ends in December.
Where is Zentalis Pharmaceuticals based?
Zentalis Pharmaceuticals's address is: 530 Seventh Avenue, New York, NY, United States, 10018
What is Zentalis Pharmaceuticals's ISIN number?
Zentalis Pharmaceuticals's international securities identification number is: US98943L1070
What is Zentalis Pharmaceuticals's CUSIP number?
Zentalis Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 98943L107

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site